Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siponimod in advancing relapsing multiple sclerosis (EXCHANGE)
NCT03623243Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2019
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of siponimod in multiple sclerosis (MS), sponsored by Novartis. Started Feb 2019; status: completed.
02
Drugs
siponimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03623243.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03623243.